Phathom Pharmaceuticals, Inc. (PHAT)


-0.20 (-1.82%)
Symbol PHAT
Price $10.77
Beta 0.757
Volume Avg. 0.29M
Market Cap 421.917M
Shares () -
52 Week Range 6.095-34.36
1y Target Est -
DCF Unlevered PHAT DCF ->
DCF Levered PHAT LDCF ->
ROE -526.69% Strong Sell
ROA -127.46% Strong Sell
Operating Margin -
Debt / Equity -3150.03% Strong Sell
P/E -
P/B -58.88 Strong Sell


Consensus EPS

Upgrades & Downgrades

Latest PHAT news

Ms. Terrie J. Curran
NASDAQ Global Select

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.